Edition:
India

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,699.80GBp
15 Nov 2019
Change (% chg)

-1.40 (-0.08%)
Prev Close
1,701.20
Open
1,705.00
Day's High
1,710.40
Day's Low
1,677.80
Volume
11,176,523
Avg. Vol
6,763,253
52-wk High
1,796.40
52-wk Low
1,408.80

Latest Key Developments (Source: Significant Developments)

GSK Says Phase 3 Study Of Nucala (Mepolizumab) Meets Primary Endpoint
Wednesday, 13 Nov 2019 

Nov 13 (Reuters) - GlaxoSmithKline PLC ::NUCALA (MEPOLIZUMAB) IS THE FIRST TREATMENT TO SHOW A SIGNIFICANT REDUCTION IN FLARES FOR PATIENTS WITH HYPEREOSINOPHILIC SYNDROME (HES).PHASE 3 STUDY MET ITS PRIMARY ENDPOINT FROM PIVOTAL STUDY OF NUCALA (MEPOLIZUMAB).SECONDARY ENDPOINTS FROM STUDY OF NUCALA (MEPOLIZUMAB) WERE ALSO STATISTICALLY SIGNIFICANT AND SUPPORTED PRIMARY ENDPOINT.BASED ON DATA FROM STUDY OF NUCALA (MEPOLIZUMAB) GSK PLANS TO PROGRESS REGULATORY SUBMISSIONS IN 2020.  Full Article

GlaxoSmithKline Upgrades 2019 Adjusted EPS Guidance
Wednesday, 30 Oct 2019 

Oct 30 (Reuters) - GlaxoSmithKline Plc ::Q3 ADJUSTED EPS ROSE 9 PERCENT TO 38.6 PENCE.Q3 SALES ROSE 16 PERCENT TO 9.4 BILLION STG.2019 ADJUSTED EPS GUIDANCE IMPROVED TO EXPECTATION OF AROUND FLAT AT CER FROM A DECLINE OF -3% TO -5%.QTRLY SALES FROM PHARMACEUTICALS £4.5 BILLION +7% AER, +3% CER.QTRLY SALES FROM VACCINES £2.3 BILLION +20% AER, +15% CER.QTRLY SHINGRIX SALES £535 MILLION +87% AER, +76% CER DRIVEN BY CONTINUING STRONG EXECUTION IN US.QTRLY SALES FROM CONSUMER HEALTHCARE £2.5 BILLION +30% AER, +25% CER (PRO-FORMA GROWTH +3% CER).QTRLY EARNINGS PER SHARE 31.4P.Q3 EARNINGS PER SHARE VIEW 33.34 PENCE, REVENUE VIEW 9.05 BILLION STG -- REFINITIV IBES DATA.GLAXOSMITHKLINE CEO EMMA WALMSLEY SAYS "GSK HAS MADE FURTHER GOOD PROGRESS IN Q3, WITH SALES GROWTH ACROSS ALL THREE BUSINESSES".FY2019 EARNINGS PER SHARE VIEW 117.40 PENCE -- REFINITIV IBES DATA.19P DIVIDEND DECLARED FOR QUARTER, CONTINUE TO EXPECT 80P FOR FY19.IN ONCOLOGY, ON TRACK TO FILE THREE INNOVATIVE MEDICINES BY YEAR END.NEW 2019 EPS VIEW REFLECTS OPERATING PERFORMANCE IN 9 MONTHS, INCREASED INVESTMENT IN RESEARCH AND DEVELOPMENT & PRIORITY ASSETS, LOWER EXPECTED EFFECTIVE TAX RATE.  Full Article

GSK Says Intravenous Benlysta Is First Biologic Treatment To Be Approved For Children With Lupus In Europe
Tuesday, 29 Oct 2019 

Oct 29 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE - INTRAVENOUS BENLYSTA IS FIRST BIOLOGIC TREATMENT TO BE APPROVED FOR CHILDREN WITH LUPUS IN EUROPE.GSK - EC DECIDED TO EXTEND TO CHILDREN 5 YRS & OLDER, EXISTING ADULT INDICATION FOR BELIMUMAB AS ADD-ON THERAPY IN PATIENTS WITH LUPUS.  Full Article

Pfizer Reports Q3 Earnings Per Share $1.36
Tuesday, 29 Oct 2019 

Oct 29 (Reuters) - Pfizer Inc ::PFIZER REPORTS THIRD-QUARTER 2019 RESULTS.Q3 EARNINGS PER SHARE $1.36.Q3 EARNINGS PER SHARE ESTIMATE $0.62 -- REFINITIV IBES DATA.Q3 ADJUSTED EARNINGS PER SHARE $0.75.UPDATED CERTAIN 2019 FINANCIAL GUIDANCE RANGES.SEES FY 2019 REVENUE $51.2 TO $52.2 BILLION.QTRLY 2019 REVENUES OF $12.7 BILLION, REFLECTING 3% OPERATIONAL DECLINE.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $2.94 TO $3.00.RAISED MIDPOINT OF 2019 GUIDANCE RANGE FOR REVENUES BY $0.2 BILLION DRIVEN BY A $0.4 BILLION OPERATIONAL IMPROVEMENT.FY2019 EARNINGS PER SHARE VIEW $2.82, REVENUE VIEW $51.32 BILLION -- REFINITIV IBES DATA.QTRLY BIOPHARMA REVENUE $10,108 MILLION VERSUS $9,422 MILLION.IN QUARTER, UPJOHN REVENUES WERE NEGATIVELY IMPACTED PRIMARILY BY JULY 2019 LOSS OF EXCLUSIVITY OF LYRICA IN U.S..QTRLY REVENUE, EXCLUDING IMPACT FROM CONSUMER HEALTHCARE, WERE FLAT OPERATIONALLY.IN QUARTER, CONSUMER HEALTHCARE REVENUES DECLINED AS A RESULT OF COMPLETION OF JV TRANSACTION WITH GSK DURING QUARTER.PFIZER - UPDATED 2019 FINANCIAL GUIDANCE PRIMARILY TO REFLECT FINANCIAL RESULTS THROUGH FIRST NINE MONTHS, CONFIDENCE IN BUSINESS GOING FORWARD.NOW EXPECTS UPJOHN REVENUES IN CHINA TO GROW BY MID-TO-HIGH-SINGLE DIGITS OPERATIONALLY FOR FULL-YEAR 2019 COMPARED WITH 2018.QTRLY UPJOHN REVENUE $2.2 BILLION, DOWN 26% OPERATIONALLY, PRIMARILY DRIVEN BY SIGNIFICANT VOLUME DECLINES FOR LYRICA IN U.S..Q3 REVENUE VIEW $12.26 BILLION -- REFINITIV IBES DATA.  Full Article

GSK starts late-stage trial for experimental antibiotic
Monday, 28 Oct 2019 

Oct 28 (Reuters) - GlaxoSmithKline PLC ::GSK STARTS A PHASE III CLINICAL PROGRAMME FOR A POTENTIAL FIRST-IN-CLASS ANTIBIOTIC, GEPOTIDACIN.GSK SAYS TRIAL INVESTIGATING USE OF GEPOTIDACIN FOR UNCOMPLICATED URINARY TRACT INFECTION AND UROGENITAL GONORRHOEA.GSK - PHASE III PROGRAMME HAS TWO STUDIES, ONE COMPARING GEPOTIDACIN TO CEFTRIAXONE PLUS AZITHROMYCIN, SECOND TO COMPARE GEPOTIDACIN TO NITROFURANTOIN.GSK SAYS FIRST RESULTS FROM PROGRAMME ARE EXPECTED BY THE END OF 2021.  Full Article

GSK Divests Two Travel Vaccines For Potential Consideration Of Up To EUR 955 Mln
Monday, 21 Oct 2019 

Oct 21 (Reuters) - GlaxoSmithKline PLC ::GSK DIVESTS TWO TRAVEL VACCINES TO BAVARIAN NORDIC.TO RECEIVE UPFRONT PAYMENT OF APPROXIMATELY EUR301 MILLION (£259M) AND MILESTONE PAYMENTS FOR A TOTAL CONSIDERATION OF UP TO EUR955 MILLION (£822M).VALUE OF INVENTORY AT ANTICIPATED CLOSING DATE IS ESTIMATED TO BE EUR 159 MILLION.NO EMPLOYEES OR MANUFACTURING FACILITIES ARE BEING TRANSFERRED AS PART OF THIS TRANSACTION.NO EMPLOYEES OR MANUFACTURING FACILITIES ARE BEING TRANSFERRED AS PART OF TRANSACTION.DIVESTMENT OF TRAVEL VACCINES RABIPUR FOR PREVENTION OF RABIES, AND ENCEPUR FOR PREVENTION OF TICK-BORNE ENCEPHALITIS, TO BAVARIAN NORDIC.VACCINES BEING DIVESTED TO BE MANUFACTURED PRIMARILY AT MARBURG SITE IN GERMANY UNTIL FULL PRODUCTION TRANSFERRED TO BAVARIAN NORDIC.DEAL EXPECTED TO CLOSE BY END OF 2019, CONDITIONAL ON ANTI-TRUST APPROVAL AND APPROVAL OF BAVARIAN NORDIC'S RIGHTS ISSUE BY ITS SHAREHOLDERS.  Full Article

Bavarian Nordic Agrees To Buy Two Vaccines From GlaxoSmithKline
Monday, 21 Oct 2019 

Oct 21 (Reuters) - Bavarian Nordic A/S ::REG-BAVARIAN NORDIC ANNOUNCES A TRANSFORMATIVE ACQUISITION OF TWO ESTABLISHED COMMERCIAL VACCINES FROM GLAXOSMITHKLINE.REG-BAVARIAN NORDIC ANNOUNCES A TRANSFORMATIVE ACQUISITION OF TWO ESTABLISHED COMMERCIAL VACCINES FROM GLAXOSMITHKLINE.UPFRONT PAYMENT TO BE FINANCED THROUGH EXISTING CASH AND BRIDGE FINANCING, TO BE REPAID BY A PLANNED FULLY UNDERWRITTEN RIGHTS ISSUE IN H1 2020.UPDATES ON 2019 FINANCIAL GUIDANCE.ACQUISITION PRICE OF UP TO APPROX. EUR 796 MILLION INCLUDING AN UPFRONT PAYMENT OF APPROX. EUR 301 MILLION.ADDITIONAL PAYMENTS OF UP TO EUR 495 MILLION ARE CONDITIONAL UPON ACHIEVEMENT OF MILESTONES DURING TRANSITION PERIOD OF 2020-2025.OPERATING PROFIT MARGIN (EBITDA) FROM COMBINED BUSINESS FROM THESE TWO NEW PRODUCTS ARE EXPECTED TO INCREASE GRADUALLY FROM 30-40% TO ABOVE 50% UPON FULL TRANSITION.TRANSACTION DOES NOT AFFECT COMPANY'S REVENUE AND OPERATING RESULT FOR 2019.RABIPUR/RABAVERT IS EXPECTED TO DELIVER LOW TO MID SINGLE-DIGIT ANNUAL SALES GROWTH AND ENCEPUR MID TO HIGH SINGLE-DIGIT ANNUAL SALES GROWTH..UPFRONT CASH PAYMENT TO GSK WILL DRAW ON COMPANY'S EXISTING CASH, THUS LOWERING EXPECTED CASH PREPAREDNESS AT YEAR-END FROM DKK 1,600 MILLION (EUR 214 MILLION) TO APPROXIMATELY DKK 1,000 MILLION (EUR 134 MILLION).WILL ASSUME FULL SALES AND MARKETING RESPONSIBILITY UPON CLOSING, I.E. IMMEDIATELY FROM 2020.WILL PURCHASE REMAINING INVENTORY OF VACCINES FROM GSK AT DIFFERENT LEVELS IN SUPPLY CHAIN..  Full Article

UK's MHRA Says Teva UK Recalling Some Batches Of Ranitidine
Thursday, 17 Oct 2019 

Oct 17 (Reuters) - UK's MHRA::UK'S MHRA - ISSUED ALERT TO HEALTHCARE PROFESSIONALS, AS TEVA UK LTD IS RECALLING ALL UNEXPIRED STOCK OF CERTAIN BATCHES OF 2 TYPES OF RANITIDINE.UK'S MHRA - 2 PRODUCTS AFFECTED BY TEVA UK RECALL ARE RANITIDINE EFFERVESCENT TABLETS 150 MICROGRAMS AND 300 MICROGRAMS.UK'S MHRA - TEVA UK RECALL IS PRECAUTIONARY MEASURE DUE TO POSSIBLE CONTAMINATION OF ACTIVE SUBSTANCE IN ZANTAC, RANITIDINE WITH IMPURITY CALLED NDMA.UK'S MHRA - ON TEVA UK LTD'S RANITIDINE RECALL, ALL REMAINING STOCK SHOULD BE QUARANTINED AND RETURNED WITHOUT DELAY TO THE SUPPLIER.UK'S MHRA - HEALTHCARE PROFESSIONALS HAVE BEEN TOLD TO STOP SUPPLYING THE TWO RANITIDINE PRODUCTS IMMEDIATELY.  Full Article

GSK Gets Positive CHMP Opinion For Intravenous Benlysta In Children With Lupus Aged 5 & Above
Friday, 20 Sep 2019 

Sept 20 (Reuters) - GlaxoSmithKline Plc ::RECEIVES POSITIVE CHMP OPINION FOR INTRAVENOUS BENLYSTA IN CHILDREN WITH LUPUS AGED FIVE YEARS AND ABOVE.CHMP OPINION FOR INTRAVENOUS BENLYSTA FOLLOWS RECENT APPROVAL BY FOOD AND DRUG ADMINISTRATION IN APRIL 2019.  Full Article

Microsoft - Charles Noski And Helmut Panke To Retire From Board - SEC Filing
Friday, 20 Sep 2019 

Sept 19 (Reuters) - Microsoft Corp ::MICROSOFT - CHARLES H. NOSKI AND HELMUT PANKE HAVE INFORMED COMPANY THEY HAVE DECIDED TO RETIRE FROM BOARD - SEC FILING.MICROSOFT - ANNOUNCED NOMINATION OF EMMA WALMSLEY, CEO OF GLAXOSMITHKLINE (GSK) AND MEMBER OF GSK BOARD, TO MICROSOFT BOARD OF DIRECTORS.MICROSOFT - ANNOUNCED NOMINATION OF EMMA WALMSLEY, CEO OF GLAXOSMITHKLINE AND MEMBER OF GSK BOARD, TO MICROSOFT BOARD OF DIRECTORS.MICROSOFT - IF WALMSLEY AND REST OF CO'S NOMINEES ARE ELECTED, BOARD WILL CONSIST OF 13 MEMBERS.  Full Article

Photo

GSK sees breakthrough in shingles vaccine output in 2024

WAVRE, Belgium GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.